http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6272618-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eaedc4b4bfa2b63425ed91307310fecd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 1985-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b3f82b8528399a6ef4208ead2ade429 |
| publicationDate | 1987-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6272618-A |
| titleOfInvention | Azathioprine preparation |
| abstract | PURPOSE: The titled preparation useful as an immunosuppressive agent, avoiding high eliminating effect on initial passage of the liver, raising extremely bioavailability and reducing side effects such as gastrointestinal disorder, etc., obtained by making azathioprine into a renal administration preparation. n CONSTITUTION: Azathioprine {chemical name: 6-[(1-methyl-4-nitroimidazol-5-yl) thio]prine} is an immunosuppressive agent for preventing rejection of a patient transplanted with an organ, especially the kidney. Its oral administration has high eliminating effect on initial passage of the liver and low bioavailability, but conversion azathioprine into renal administration can raise bioavailability by two times or more than oral administration. When intramuscular injection is difficult, the drug can be released for body circulation. Production of suppository is carried out by conventional procedure and 250W400mg azathioprine is preferably contained per suppository. n COPYRIGHT: (C)1987,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9630021-A1 |
| priorityDate | 1985-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 17.